Desafios da medição da glucose
Dr. David Grenache reveals
- Release Date: 03.03.2025
- Duration: 23 minutes
- Guest: Dr. David Grenache
- Host: Director Global Medical & Clinical Affairs Ana-Maria Šimundić
- Introduction: Dr. David Grenache, now retired, former Chief Scientific Officer at TriCore Reference Labs in Alberquerque, New Mexico, shares his views on glucose stabilization methods with our host Ana-Maria Šimundić.
Timestamps for Episode 2
- 00:17 - Introducing David Grenache
- 02:55 - The challenge of glucose testing lies in its rapid decline unless it can be processed immediately or stabilized appropriately
- 04:13 - How laboratories try to stabilize glucose and why these methods are not perfect
- 05:56 - What does the VACUETTE® FC Mix tube by Greiner Bio-One do?
- 08:28 - How are samples handled at TriCore lab?
- 10:08 - What about processing samples that have had to be transported long-distance?
- 11:32 - Decision limits (cutoffs) for the diagnosis of diabetes mellitus
- 18:22 - Should there be some standardization for glucose testing? Are there guidelines?
- 20:00 - What is the potential for citrate tubes besides glucose?
What You Can't Miss – In a Nutshell
Stabilizing glucose has a great impact on diagnoses rates of diabetes
- Glucose declines rapidly in whole blood - at a rate of 7-8% per hour - so preventing this decline is important for accurate diagnosis of diabetes mellitus
Some stabilization methods are imperfect or impractical
- Sodium fluoride is a commonly used stabilizer, but whilst it inhibits enolase in the glycolytic pathway, other enzymes remain active and continue to metabolize glucose
Using a VACUETTE® FC Mix tube does the job
- FC Mix tubes contain fluoride to inhibit enolase, citric acid to acidify the sample and inhibit other glycolytic enzymes, as well as EDTA that chelates the magnesium.
“VACUETTE® FC Mix tubes contain citric acid in addition to fluoride, enable acidification of the sample and inhibit other glycolytic enzyzmes. Additionally, EDTA chelates the magnesium, a cofactor for enzyzme activity.”
Get the latest from our podcast
Disclaimer & Shownotes
The guests interviewed in this podcast share their individual experiences with the use of our or comparable products and/or services. The opinions expressed are those of the interviewee and do not claim to represent the opinions or views of Greiner Bio-One. This information partially reflects the opinions of our customers and/or the experiences of individuals and does not claim to represent the opinions or views of Greiner Bio-One.
Products from Greiner Bio-One should only be used by appropriately trained medical professionals in accordance with the relevant instructions for use (IFU). A list of indications, contraindications, precautions, and warnings can be found in the instructions for use that accompany each product or can be downloaded from our website www.gbo.com (Download Center). For further information, please contact your local Greiner Bio-One distributor or visit our website.
All information is provided without guarantee despite careful processing. Liability, warranty, or guarantee of Greiner Bio-One GmbH is excluded. All rights, errors, and changes are reserved. Unless otherwise stated, Greiner Bio-One GmbH holds all copyrights and/or other (usage) rights in the present documents, especially to trademarks, such as the listed (word-image) marks, logos. Any use, reproduction, or other use of the rights of Greiner Bio-One GmbH is expressly prohibited.
Publisher and editor: Greiner Bio-One GmbH, Bad Haller Str. 32, 4550 Kremsmünster, Austria.
Assiamira Ferrara, Monique M. Hedderson, Charles P. Quesenberry, Joseph V. Selby; Prevalence of Gestational Diabetes Mellitus Detected by the National Diabetes Data Group or the Carpenter and Coustan Plasma Glucose Thresholds. Diabetes Care 1 September 2002; 25 (9): 1625–1630. doi.org/10.2337/diacare.25.9.1625
diabetesjournals.org/care/article/25/9/1625/21728/Prevalence-of-Gestational-Diabetes-Mellitus
